In:
International Journal of Cancer, Wiley, Vol. 144, No. 5 ( 2019-03), p. 1104-1114
Abstract:
What's new? Small‐cell lung cancer (SCLC) is a highly aggressive and metastatic neuroendocrine carcinoma with no therapeutic improvement in decades. SSTR2 is canonically viewed as an inhibitory receptor on cell growth, but trials have shown poor clinical responses to agonists. This work shows that SCLC cell lines and primary tumors express high levels of SSTR2, and high SSTR2 expression is correlated with worse patient survival in SCLC. Furthermore, SSTR2 signaling rather serves as an important protumor survival signal in a subset of SCLC cell lines/tumor tissues, with loss of SSTR2 expression leading to profound effects on apoptosis with significant clinical implications.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2019
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8
Bookmarklink